Eli Lilly announced it will begin rollout of its first connected platform, the Tempo Personalized Diabetes Management Platform, later this year in the U.S. "The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins," the company stated. "Lilly has over a century of knowledge of insulin and its complexities, and recognizes the emotional impact of managing diabetes. Launching this platform is an opportunity for us to more broadly support those who rely on our insulins," added Kevin Cammack, Head of Connected Care, Lilly Diabetes.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- FDA doesn’t see bebtelovimab neutralizing Omicron subvariants BQ.1, BQ.1.1
- Eli Lilly reports EMPA-KIDNEY phase 3 clinical trial met primary endpoint
- Jim Cramer Says These 2 ‘Strong Buy’ Stocks Could Be Among the New Market Leaders
- Eli Lilly price target raised to $365 from $305 at Wells Fargo
- Eli Lilly price target raised to $395 from $355 at Barclays
